As of December 15, 2025, Palantir Bioceuticals Inc (IFAN) reports a ROE (Return on Equity) of -66.49%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Palantir Bioceuticals Inc's ROE (Return on Equity)
Over recent years, Palantir Bioceuticals Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-12-31 | -66.49% |
| 2021-12-31 | -1.17% |
| 2016-08-31 | 64.96% |
| 2015-08-31 | 61.60% |
| 2014-08-31 | 20.04% |
This fluctuation highlights how Palantir Bioceuticals Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Palantir Bioceuticals Inc's ROE (Return on Equity) to Peers
To better understand Palantir Bioceuticals Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Palantir Bioceuticals Inc (IFAN) | -66.49% |
| GTFN Holdings Inc (BTOW) | 1433.76% |
| Mygo Games Holding Co (MYGG) | 1279.58% |
| Plyzer Technologies Inc (PLYZ) | 1013.34% |
| Go-Page Corp (GOPG) | 309.06% |
| Arias Intel Corp (ASNT) | 305.21% |
Compared to its competitors, Palantir Bioceuticals Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.